Jefferies Financial Group Inc. Acquires 9,882 Shares of IDEXX Laboratories, Inc. $IDXX

Jefferies Financial Group Inc. boosted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 659.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 11,380 shares of the company’s stock after purchasing an additional 9,882 shares during the period. Jefferies Financial Group Inc.’s holdings in IDEXX Laboratories were worth $5,943,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Bank of New York Mellon Corp bought a new position in IDEXX Laboratories in the 2nd quarter valued at $628,223,000. Arrowstreet Capital Limited Partnership increased its position in shares of IDEXX Laboratories by 52.4% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company’s stock valued at $471,335,000 after purchasing an additional 288,471 shares during the last quarter. International Assets Investment Management LLC raised its stake in shares of IDEXX Laboratories by 30,484.1% during the 3rd quarter. International Assets Investment Management LLC now owns 234,274 shares of the company’s stock worth $122,336,000 after purchasing an additional 233,508 shares during the period. Alyeska Investment Group L.P. raised its stake in shares of IDEXX Laboratories by 97.3% during the 2nd quarter. Alyeska Investment Group L.P. now owns 401,082 shares of the company’s stock worth $211,146,000 after purchasing an additional 197,808 shares during the period. Finally, American Capital Management Inc. bought a new stake in shares of IDEXX Laboratories during the 2nd quarter worth $85,341,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insider Activity

In other IDEXX Laboratories news, insider Jonathan Mazelsky sold 25,140 shares of the firm’s stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $703.19, for a total value of $17,678,196.60. Following the completion of the transaction, the insider owned 83,803 shares in the company, valued at $58,929,431.57. This trade represents a 23.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Sharon E. Underberg sold 8,906 shares of the firm’s stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $688.59, for a total transaction of $6,132,582.54. Following the completion of the transaction, the executive vice president owned 7,169 shares of the company’s stock, valued at $4,936,501.71. This trade represents a 55.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 41,428 shares of company stock valued at $28,567,934. 0.79% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $698.02 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.19 and a quick ratio of 0.88. The business has a fifty day simple moving average of $558.91 and a two-hundred day simple moving average of $573.47. IDEXX Laboratories, Inc. has a 1 year low of $500.61 and a 1 year high of $769.98. The company has a market capitalization of $55.00 billion, a P/E ratio of 47.07 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, November 2nd. The company reported $3.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.71 by $0.25. The firm had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.19 billion. IDEXX Laboratories had a return on equity of 71.04% and a net margin of 25.36%. The business’s revenue was up 9.9% on a year-over-year basis. During the same period in the previous year, the company posted $3.22 earnings per share. On average, analysts expect that IDEXX Laboratories, Inc. will post 15.05 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on IDXX shares. UBS Group boosted their price target on shares of IDEXX Laboratories from $627.00 to $700.00 and gave the stock a “neutral” rating in a report on Tuesday, November 3rd. Citigroup raised their price objective on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. BTIG Research dropped coverage on shares of IDEXX Laboratories in a research report on Friday, October 30th. They issued a “buy” rating on the stock. The Goldman Sachs Group started coverage on shares of IDEXX Laboratories in a research note on Friday, October 16th. They issued a “buy” rating and a $740.00 target price on the stock. Finally, JPMorgan Chase & Co. dropped their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating on the stock in a research note on Friday, October 16th. Seven investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $717.27.

IDEXX Laboratories Profile

IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices. The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.